Blog

Plumbing the core and nibbling at the margins of cancer

The Importance of Clinical Trial Matching

Adrienne Craig-Kennard, MBA, VP Global Business Development & Strategic Alliances at CollabRx Follow David Q: You have served as Vice President, Global Business Development and Strategic Alliances of CollabRx for more than one year. How do you rank the importance of the CollabRx Clinical Trial Matcher in the “big picture” of cancer care? A: Thousands […]

Clinical Trial Matching for Patients with Molecularly Characterized Tumors

Smruti Vidwans, PhD, Chief Science Officer at CollabRx Q: Clinical Trials is such an important topic, but it is so broad. Is there a way to provide better matching for Clinical Trials involving cancer patients, especially those whose cancers may have the added diagnostic information of molecular profiling? A: Clinical trials provide cancer patients, especially […]

Best Use of Palliative Care in Cancer Patients

Malinda Bell, MD, Associate Professor Michigan State University College of Human Medicine; Clinical Associate Professor Western Michigan University Dept of Emergency Medicine Q: Many, even millions, of Americans are living with advanced cancer. You are a board certified Emergency Physician and also boarded in Palliative Care. Please explain the fundamental premises, promises, and practices of […]

Will Advanced Computing Help Eradicate Cancer?

Helen Sadik, PhD, Scientific Knowledge Engineer, CollabRx Q: Computers and artificial intelligence show both great progress and great promise in many fields. Can “Big Data”, A.I., and the Watson ilk devise a way to end cancer? A: In 2011, a young and emotionless Watson grabbed the tech industry’s attention by dominating Jeopardy’s two greatest champions. […]

The Essential Value of the International Committee of Medical Journal Editors (ICMJE)

Catherine D. DeAngelis, MD, University Distinguished Professor Emerita, Johns Hopkins University School of Medicine; Professor of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health; Editor in Chief Emerita, JAMA Q: The internet has produced mass democratization of information provision and access with little quality control. You represented JAMA at the International Committee […]

Making Cancer Care Great Again

Michael L. Millenson, President of Health Quality Advisors LLC and an Adjunct Associate Professor of Medicine at Northwestern’s Feinberg School of Medicine Q: Donald Trump’s campaign for the presidency included a promise to repeal “Obamacare” in its entirety. If he succeeds in fulfilling that promise, what impact can we expect on American cancer prevention and […]

How to Control American Drug Costs

Brian Klepper PhD, Health Care Analyst, CEO of Health Value Direct and an advisor to The Lundberg Institute Q: Many newer (as well as many older) drugs are of great value in treating many diseases. But the prices charged seem very high and rising, causing serious concern for many. Is there anything the United States […]

Expanded-Compassionate Use of an Investigational Drug

Vivek Subbiah, MD, Assistant Professor, Department of Investigational Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Q: You have exhausted surgical, radiation, and standard chemotherapy options for a patient with an advanced epithelial malignancy. Yet the patient has a strong will to live and to advance science during […]

The “Hutch” and Improving Baseball: World Series Edition

Jerald P. Radich, MD, Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine, Seattle, Washington. Q: You are known to be good at clever solutions to daunting problems, and a baseball fan to boot. What should we do about […]

How to Decide to Offer a New Lab Test

Jared N. Schwartz, MD PhD LLC Past President, College of American Pathologists; Opinions his own; Charlotte, NC Q: Pathologists are faced with the need to set up additional lab tests routinely. Immunotherapy for cancer is the current rage. How does a pathologist decide whether and how to offer a new test such as PD-L1 Expression […]